ROBERT KIRK DAVIS
Pilots at Aldergate Dr, Arlington, TX
License number
Texas A2775084
Issued Date
Aug 2016
Expiration Date
Aug 2018
Category
Airmen
Type
Authorized Aircraft Instructor
Address
Address
2305 Aldergate Dr, Arlington, TX 76012
Professional information
Robert Davis - Arlington, TX
Work:
Holt Chrysler Jeep Dodge - Arlington, TX
Service Advisor Manny Towing - Arlington, TX
Tow Truck Driver Quality Drive Away - Goshen, IN
Drive Away Driver Arrive On Time Delivery - Dallas, TX
Route and Hot Shot Courier Nokico - Lewisville, TX
Contractor RTUI
Contractor Whelan Security - Dallas, TX
Security Director/Lead Field Supervisor Smith Protective Services - Dallas, TX
Commissioned Security Officer- Motor Patrol/Field Supervisor Durham School Services - McKinney, TX
School & Special Needs Driver, Dispatcher self employed - McKinney, TX
Registered Massage Therapist Llano Construction Company - Corinth, TX
Heavy Equipment Mechanic Dallas AirMotive, Inc - Dallas, TX
Aircraft Engine Mechanic McKinney Executive Air - McKinney, TX
Aircraft Mechanic
Service Advisor Manny Towing - Arlington, TX
Tow Truck Driver Quality Drive Away - Goshen, IN
Drive Away Driver Arrive On Time Delivery - Dallas, TX
Route and Hot Shot Courier Nokico - Lewisville, TX
Contractor RTUI
Contractor Whelan Security - Dallas, TX
Security Director/Lead Field Supervisor Smith Protective Services - Dallas, TX
Commissioned Security Officer- Motor Patrol/Field Supervisor Durham School Services - McKinney, TX
School & Special Needs Driver, Dispatcher self employed - McKinney, TX
Registered Massage Therapist Llano Construction Company - Corinth, TX
Heavy Equipment Mechanic Dallas AirMotive, Inc - Dallas, TX
Aircraft Engine Mechanic McKinney Executive Air - McKinney, TX
Aircraft Mechanic
Guaifenesin Sustained Release Formulation And Tablets
US Patent:
6372252, Apr 16, 2002
Filed:
Apr 28, 2000
Appl. No.:
09/559542
Inventors:
Ralph W. Blume - Fort Worth TX
Robert D. Davis - Arlington TX
Donald Jeffrey Keyser - Southlake TX
Robert D. Davis - Arlington TX
Donald Jeffrey Keyser - Southlake TX
Assignee:
Adams Laboratories, Inc. - Ft. Worth TX
International Classification:
A61K 920
US Classification:
424464, 424400, 424468, 424472, 424474, 424475
Abstract:
The invention relates to a novel pharmaceutical sustained release formulation of guaifenesin. The formulation may comprise a hydrophilic polymer, preferably a hydroxypropyl methylcellulose, and a water-insoluble polymer, preferably an acrylic resin, in a ratio range of about one-to-one (1:1) to about six-to-one (6:1), more preferably a range of about three-to-two (3:2) to about four-to-one (4:1), and most preferably about two-to-one (2:1), by weight. This formulation capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject. The invention also relates to a modified release guaifenesin tablet which has two portion: the first portion comprises an immediate release formulation of guaifenesin and the second portion comprises a sustained release formulation of guaifenesin as described above. This two portion, or bi-layer, tablet has a maximum serum concentration equivalent to that of an immediate release guaifenesin tablet, and is capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject.
Sustained Release Of Guaifenesin
US Patent:
7838032, Nov 23, 2010
Filed:
Apr 4, 2003
Appl. No.:
10/406557
Inventors:
Robert D. Davis - Arlington TX, US
Ralph W. Blume - Fort Worth TX, US
Donald Jeffrey Keyser - Southlake TX, US
Ralph W. Blume - Fort Worth TX, US
Donald Jeffrey Keyser - Southlake TX, US
Assignee:
Reckitt Benckiser Inc. - Parsippany NJ
International Classification:
A61K 9/22
US Classification:
424468, 424452, 424457, 424474
Abstract:
The invention relates to a novel pharmaceutical sustained release formulation of guaifenesin. The formulation may comprise a hydrophilic polymer, preferably a hydroxypropyl methylcellulose, and a water-insoluble polymer, preferably an acrylic resin, in a ratio range of about one-to-one (1:1) to about nine-to-one (9:1), more preferably a range of about three-to-two (3:2) to about six-to-one (6:1), and most preferably in a range of about two-to-one (2:1) to about four-to-one (4:1) by weight. This formulation capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject. The invention also relates to a modified release product which has two portions: a first portion having an immediate release formulation of guaifenesin and a second portion having a sustained release formulation of guaifenesin. The modified release product has a maximum guaifenesin serum concentration equivalent to that of an immediate release guaifenesin tablet, and is capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject.
Sustained Release Of Guaifenesin Combination Drugs
US Patent:
8012504, Sep 6, 2011
Filed:
Apr 15, 2003
Appl. No.:
10/413530
Inventors:
Robert D. Davis - Arlington TX, US
Ralph W. Blume - Fort Worth TX, US
Donald Jeffrey Keyser - Southlake TX, US
Ralph W. Blume - Fort Worth TX, US
Donald Jeffrey Keyser - Southlake TX, US
Assignee:
Reckitt Benckiser Inc. - Parsippany NJ
International Classification:
A61K 9/22
US Classification:
424468, 424452, 424457, 424474
Abstract:
The invention relates to a novel pharmaceutical modified release formulation of guaifenesin and dextromethorphan. The formulation may comprise a hydrophilic polymer, preferably a hydroxypropyl methylcellulose, and a water-insoluble polymer, preferably an acrylic resin, in a ratio range of about one-to-one (1:1) to about nine-to-one (9:1), more preferably a range of about three-to-two (3:2) to about six-to-one (6:1), and most preferably in a range of about two-to-one (2:1) to about four-to-one (4:1) by weight. This formulation capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject. The invention also relates to a modified release product which has two portions: a first portion having an immediate release formulation of guaifenesin and a second portion having a sustained release formulation of guaifenesin, wherein one or both portions further comprises dextromethorphan. The modified release product has a maximum guaifenesin serum concentration equivalent to that of an immediate release guaifenesin tablet, and is capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject.
Sustained Release Formulations Of Guaifenesin And Additional Drug Ingredients
US Patent:
6955821, Oct 18, 2005
Filed:
Apr 15, 2002
Appl. No.:
10/121706
Inventors:
Robert D. Davis - Arlington TX, US
Ralph W. Blume - Fort Worth TX, US
Donald Jeffrey Keyser - Southlake TX, US
Ralph W. Blume - Fort Worth TX, US
Donald Jeffrey Keyser - Southlake TX, US
Assignee:
Adams Laboratories, Inc. - Fort Worth TX
International Classification:
A61K009/20, A61K009/22, A61K009/26, A61K009/48, A61K009/52
US Classification:
424468, 424451, 424452, 424457, 424458, 424464, 424465, 424469
Abstract:
The invention relates to a novel pharmaceutical sustained release formulation of guaifenesin and at least one additional drug ingredient. The formulation may comprise a hydrophilic polymer, preferably a hydroxypropyl methylcellulose, and a water-insoluble polymer, preferably an acrylic resin, in a ratio range of about one-to-one (1:1) to about nine-to-one (9:1), more preferably a range of about three-to-two (3:2) to about six-to-one (6:1), and most preferably in a range of about two-to-one (2:1) to about four-to-one (4:1) by weight. This formulation capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject. The invention also relates to a modified release product which has two portions: a first portion having an immediate release formulation of guaifenesin and a second portion having a sustained release formulation of guaifenesin, wherein one or both portions has at least one additional drug ingredient. The modified release product has a maximum guaifenesin serum concentration equivalent to that of an immediate release guaifenesin tablet, and is capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject.
Sustained Release Formulations Of Guaifenesin And Additional Drug Ingredients
US Patent:
7985421, Jul 26, 2011
Filed:
Jun 22, 2005
Appl. No.:
11/158012
Inventors:
Robert D. Davis - Arlington TX, US
Ralph W. Blume - Fort Worth TX, US
Donald Jeffrey Keyser - Southlake TX, US
Ralph W. Blume - Fort Worth TX, US
Donald Jeffrey Keyser - Southlake TX, US
Assignee:
Reckitt Benckiser Inc. - Parsippany NJ
International Classification:
A61K 9/22
US Classification:
424468, 424452, 424457, 424474
Abstract:
The invention relates to a novel pharmaceutical sustained release formulation of guaifenesin and at least one additional drug ingredient. The formulation may comprise a hydrophilic polymer, preferably a hydroxypropyl methylcellulose, and a water-insoluble polymer, preferably an acrylic resin, in a ratio range of about one-to-one (1:1) to about nine-to-one (9:1), more preferably a range of about three-to-two (3:2) to about six-to-one (6:1), and most preferably in a range of about two-to-one (2:1) to about four-to-one (4:1) by weight. This formulation capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject. The invention also relates to a modified release product which has two portions: a first portion having an immediate release formulation of guaifenesin and a second portion having a sustained release formulation of guaifenesin, wherein one or both portions has at least one additional drug ingredient. The modified release product has a maximum guaifenesin serum concentration equivalent to that of an immediate release guaifenesin tablet, and is capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject.
Sustained Release Of Guaifenesin
US Patent:
2011005, Mar 3, 2011
Filed:
Nov 5, 2010
Appl. No.:
12/940781
Inventors:
Robert D. Davis - Arlington TX, US
Ralph W. Blume - Fort Worth TX, US
Donald Jeffrey Keyser - Southlake TX, US
Ralph W. Blume - Fort Worth TX, US
Donald Jeffrey Keyser - Southlake TX, US
Assignee:
RECKITT BENCKISER INC. - Parsippany NJ
International Classification:
A61K 9/24, A61K 31/09, A61P 11/10
US Classification:
424472, 514718
Abstract:
The invention relates to a novel pharmaceutical sustained release formulation of guaifenesin. The formulation may comprise a hydrophilic polymer, preferably a hydroxypropyl methylcellulose, and a water-insoluble polymer, preferably an acrylic resin, in a ratio range of about one-to-one (1: 1) to about nine-to-one (9: 1), more preferably a range of about three-to-two (3:2) to about six-to-one (6: 1), and most preferably in a range of about two-to-one (2: 1) to about four-to-one (4: 1) by weight. This formulation capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject. The invention also relates to a modified release product which has two portions: a first portion having an immediate release formulation of guaifenesin and a second portion having a sustained release formulation of guaifenesin. The modified release product has a maximum guaifenesin serum concentration equivalent to that of an immediate release guaifenesin tablet, and is capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject.
Sustained Release Of Guaifenesin Combination Drugs
US Patent:
7985420, Jul 26, 2011
Filed:
Apr 4, 2003
Appl. No.:
10/406574
Inventors:
Robert D. Davis - Arlington TX, US
Ralph W. Blume - Fort Worth TX, US
Donald Jeffrey Keyser - Southlake TX, US
Ralph W. Blume - Fort Worth TX, US
Donald Jeffrey Keyser - Southlake TX, US
Assignee:
Reckitt Benckiser Inc. - Parsippany NJ
International Classification:
A61K 9/22
US Classification:
424468, 424452, 424457, 424474
Abstract:
The invention relates to a novel pharmaceutical sustained release formulation of guaifenesin and pseudoephedrine. The formulation may comprise a hydrophilic polymer, preferably a hydroxypropyl methylcellulose, and a water-insoluble polymer, preferably an acrylic resin, in a ratio range of about one-to-one (1:1) to about nine-to-one (9:1), more preferably a range of about three-to-two (3:2) to about six-to-one (6:1), and most preferably in a range of about two-to-one (2:1) to about four-to-one (4:1) by weight. This formulation capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject. The invention also relates to a modified release product which has two portions: a first portion having an immediate release formulation of guaifenesin and a second portion having a sustained release formulation of guaifenesin, wherein one or both portions further comprises pseudoephedrine. The modified release product has a maximum guaifenesin serum concentration equivalent to that of an immediate release guaifenesin tablet, and is capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject.